Effects of estrogen deprivation on human benign prostatic hyperplasia
- 31 March 1993
- journal article
- research article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 44 (4), 573-576
- https://doi.org/10.1016/0960-0760(93)90261-t
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Selective inhibition of androstenedione‐induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1‐methyl‐androsta‐1,4‐diene‐3,17‐dione (1‐methyl‐ADD)The Prostate, 1989
- Effects of the aromatase inhibitor testolactone on human benign prostatic hyperplasiaSteroids, 1987
- 1-methyl-1,4-androstadiene-3,17-dione (SH 489): Characterization of an irreversible inhibitor of estrogen biosynthesisJournal of Steroid Biochemistry, 1986
- Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: Preliminary resultsThe Prostate, 1986
- A double‐blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia.British Journal of Clinical Pharmacology, 1984
- Nuclei of stroma: Site of highest estrogen concentration in human benign prostatic hyperplasiaThe Prostate, 1982
- Light Microscopic Stereological Analysis of the Normal Human Prostate and of Benign Prostatic HyperplasiaJournal of Urology, 1979
- Correlation among Prostate Stroma, Plasma Estrogen Levels, and Urinary Estrogen Excretion in Patients with Benign Prostatic HypertrophyJournal of Clinical Endocrinology & Metabolism, 1978